Can Fite (Israel) Performance

CANF -- Israel Stock  

ILS 234.30  1.30  0.56%

Macroaxis gives Can Fite performance score of 0 on a scale of 0 to 100. The firm shows Beta (market volatility) of 0.1801 which signifies that as returns on market increase, Can Fite returns are expected to increase less than the market. However during bear market, the loss on holding Can Fite will be expected to be smaller as well.. Even though it is essential to pay attention to Can Fite BioPharma historical returns, it is always good to be careful when utilizing equity current trending patterns. Macroaxis philosophy towards foreseeing future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Can Fite BioPharma Ltd exposes twenty-one different technical indicators which can help you to evaluate its performance. Can Fite BioPharma has expected return of -0.0335%. Please be advised to confirm Can Fite BioPharma Standard Deviation, Information Ratio, Treynor Ratio, as well as the relationship between Variance and Jensen Alpha to decide if Can Fite BioPharma past performance will be repeated at some point in the near future.
Horizon     30 Days    Login   to change

Can Fite BioPharma Relative Risk vs. Return Landscape

If you would invest  23,580  in Can Fite BioPharma Ltd on September 19, 2018 and sell it today you would lose (150.00)  from holding Can Fite BioPharma Ltd or give up 0.64% of portfolio value over 30 days. Can Fite BioPharma Ltd is generating negative expected returns and assumes 1.6197% volatility on return distribution over the 30 days horizon. Simply put, 14% of equities are less volatile than Can Fite BioPharma Ltd and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, Can Fite BioPharma Ltd is expected to generate 1.52 times more return on investment than the market. However, the company is 1.52 times more volatile than its market benchmark. It trades about -0.02 of its potential returns per unit of risk. The DOW is currently generating roughly -0.15 per unit of risk.

Can Fite Market Risk Analysis

Sharpe Ratio = -0.0207
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsCANF

Can Fite Relative Performance Indicators

Estimated Market Risk
 1.62
  actual daily
 
 86 %
of total potential
  
Expected Return
 -0.03
  actual daily
 
 1 %
of total potential
  
Risk-Adjusted Return
 -0.02
  actual daily
 
 1 %
of total potential
  
Based on monthly moving average Can Fite is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Can Fite by adding it to a well-diversified portfolio.

Can Fite Performance Rating

Can Fite BioPharma Ltd Risk Adjusted Performance Analysis

0 

Risk-Adjusted Performance

Over the last 30 days Can Fite BioPharma Ltd has generated negative risk-adjusted returns adding no value to investors with long positions.

Can Fite Alerts

Equity Alerts and Improvement Suggestions

Can Fite BioPharma is not yet fully synchronised with the market data
Can Fite BioPharma generates negative expected return over the last 30 days
The company reported revenue of 1.4 M. Net Loss for the year was (4.95 M) with profit before overhead, payroll, taxes, and interest of 2.94 M.
CAN-FITE BIOPHARMA has accumulated about 8.31 M in cash with (33.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24.
Check also Trending Equities. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Search macroaxis.com